BBL
NBIX icon

Beck Bode LLC’s Neurocrine Biosciences NBIX Stock Holding History

Beck Bode LLC’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-47,658
Closed -$5.49M – 124
2024
Q3 		$5.49M Buy
+47,658
New +$6.53M 1.03% 36
2021
Q4 		– Sell
-62,740
Closed -$6.02M – 94
2021
Q3 		$6.02M Buy
+62,740
New +$5.93M 1.68% 27

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Beck Bode LLC's NBIX Position: Q4 2024 in Review

Beck Bode LLC sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 47,658 shares — an estimated $5.49M sold.

Beck Bode LLC first reported a position in NBIX in Q3 2021 and held it in 2 quarters. The position peaked at $6.02M in Q3 2021. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Beck Bode LLC reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Beck Bode LLC sold 47,658 Neurocrine Biosciences shares in Q4 2024, an estimated $5.49M.
  • Beck Bode LLC first reported a position in Neurocrine Biosciences in Q3 2021 and held it in 2 quarters.
  • Beck Bode LLC's Neurocrine Biosciences position peaked at $6.02M in Q3 2021.
  • 600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Beck Bode LLC's 13F filing for Q4 2024, filed 14 Feb 2025.